| Market Cap | 12.38B 10.76B 10.01B 9.19B 17.36B 1,181B 17.63B 118B 46.33B 588B 46.48B 45.46B 1,972B | P/E 2026 * |
54.9x | P/E 2027 * | 27.5x |
|---|---|---|---|---|---|
| Enterprise Value | 12.16B 10.57B 9.84B 9.04B 17.06B 1,161B 17.33B 116B 45.53B 578B 45.68B 44.68B 1,938B | EV / Sales 2026 * |
11.2x | EV / Sales 2027 * | 7.79x |
| Free-Float |
66.13% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Corcept Therapeutics
| 1 day | +0.16% |
| Manager | Title | Age | Since |
|---|---|---|---|
Joseph Belanoff
CEO | Chief Executive Officer | 68 | 1998-12-31 |
Atabak Mokari
DFI | Director of Finance/CFO | 49 | 2021-02-28 |
Joseph Lyon
CTO | Chief Tech/Sci/R&D Officer | 48 | 2024-01-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Belanoff
BRD | Director/Board Member | 68 | 1998-12-31 |
James Wilson
CHM | Chairman | 82 | 1998-12-31 |
David Mahoney
BRD | Director/Board Member | 71 | 2004-06-30 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.16% | +13.02% | - | - | 12.38B | |
| -0.53% | -3.95% | +55.23% | +152.74% | 1,024B | |
| +0.21% | -2.68% | +55.61% | +53.02% | 618B | |
| -2.51% | -3.25% | +32.76% | +67.76% | 443B | |
| +0.06% | -0.42% | +37.53% | +30.67% | 349B | |
| -0.14% | -0.24% | +34.41% | +39.01% | 297B | |
| -0.69% | -0.30% | +11.55% | +12.93% | 264B | |
| -7.37% | -4.40% | -2.54% | -43.87% | 209B | |
| -0.64% | +2.43% | +30.52% | +64.49% | 208B | |
| -0.82% | +0.70% | +15.96% | +71.01% | 162B | |
| Average | -1.23% | -1.20% | +30.11% | +49.75% | 397.08B | |
| Weighted average by Cap. | -0.98% | -1.93% | +39.24% | +72.95% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.08B 941M 876M 804M 1.52B 103B 1.54B 10.33B 4.05B 51.46B 4.07B 3.98B 173B | 1.53B 1.33B 1.24B 1.13B 2.14B 146B 2.18B 14.57B 5.72B 72.59B 5.74B 5.61B 243B |
| Net income | 242M 210M 196M 180M 340M 23.11B 345M 2.31B 906M 11.5B 909M 889M 38.57B | 645M 561M 522M 479M 905M 61.59B 919M 6.15B 2.41B 30.66B 2.42B 2.37B 103B |
| Net Debt | -213M -185M -173M -159M -299M -20.37B -304M -2.04B -799M -10.14B -801M -784M -34B | -474M -412M -384M -352M -665M -45.27B -676M -4.52B -1.78B -22.54B -1.78B -1.74B -75.57B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
